MedTrace Logo

Treatment of West Nile Virus With MGAWN1

NCT00927953 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2022-02-10

Study results available
· View outcomes & findings →

Summary

This study will test a drug called MGAWN1 for the treatment of West Nile infections.

Conditions

  • West Nile Neuroinvasive Disease
  • West Nile Virus Infection
  • Encephalitis
  • Meningitis
  • Acute Flaccid Paralysis
  • West Nile Fever

Interventions

BIOLOGICAL

MGAWN1

Humanized monoclonal to West Nile virus. Dose = 30 mg/kg actual body weight intravenous, one dose at Day 0.

BIOLOGICAL

Placebo - normal saline

Normal Saline intravenous, volume same as active comparator, one dose at Day 0

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • MacroGenics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2011-02-28
Completion
2011-05-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00927953 on ClinicalTrials.gov